IRB #
STUDY00017574
Title
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial
Principal Investigator
Eric Anderson
Study Purpose
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.
Medical Condition(s)
Advanced or Metastatic Non-Small Cell Lung Cancer
Eligibility Criteria
Female or male ≥18 years of age
Confirmed diagnosis of unresectable Stage IIIb (advanced) or Stage IV (metastatic) NSCLC
Age Range
18 - 120
Healthy Volunteers Needed
No
Duration of Participation
Your length in time in the study, including the screening, treatment, and follow-up periods, will be about 4-6 years.
Minors Included
No
Contact
Knight Cancer Institute Clinical Trials
trials@ohsu.edu
503 494-1080
Sponsor
F. Hoffmann-La Roche Ltd
Recruitment End
11/30/2030
Compensation Provided
No
Go Back